Dr Reddys Laboratories Ltd vs Kilitch Drugs India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1270 as of 05 May 15:30 . The P/E Ratio of Dr Reddys Laboratories Ltd changed from 38.5 on March 2021 to 16.9 on March 2025 . This represents a CAGR of -15.18% over 5 yearsThe P/E Ratio of Kilitch Drugs (India) Ltd changed from 34.2 on March 2021 to 21.8 on March 2025 . This represents a CAGR of -8.61% over 5 years The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 75095 crore on March 2021 to ₹ 95465 crore on March 2025 . This represents a CAGR of 4.92% over 5 yearsThe Market Cap of Kilitch Drugs (India) Ltd changed from ₹ 125.58 crore on March 2021 to ₹ 581.3 crore on March 2025 . This represents a CAGR of 35.86% over 5 years The revenue of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 9024 crore as compare to the Sep '25 revenue of ₹ 9158 crore. This represent the decline of -1.46% The revenue of Kilitch Drugs (India) Ltd for the Dec '25 is ₹ 55.34 crore as compare to the Sep '25 revenue of ₹ 55.58 crore. This represent the decline of -0.43% The ebitda of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 2158 crore as compare to the Sep '25 ebitda of ₹ 2340 crore. This represent the decline of -7.76% The ebitda of Kilitch Drugs (India) Ltd for the Dec '25 is ₹ 7.68 crore as compare to the Sep '25 ebitda of ₹ 11.7 crore. This represent the decline of -34.36% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1392 crore to ₹ 1189 crore over 7 quarters. This represents a CAGR of -8.60% The net profit of Kilitch Drugs (India) Ltd changed from ₹ 0.11 crore to ₹ 4.32 crore over 7 quarters. This represents a CAGR of 714.53% The Dividend Payout of Dr Reddys Laboratories Ltd changed from 19.03 % on March 2021 to 12.47 % on March 2025 . This represents a CAGR of -8.11% over 5 yearsThe Dividend Payout of Kilitch Drugs (India) Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Dr Reddys Laboratories Ltd

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe.
Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe.
Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices. The Company is engaged in development, manufacturing and marketing of quality finished dosages.
The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia.

FAQs for the comparison of Dr Reddys Laboratories Ltd and Kilitch Drugs (India) Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Kilitch Drugs (India) Ltd?

Market cap of Dr Reddys Laboratories Ltd is 106,080 Cr while Market cap of Kilitch Drugs (India) Ltd is 531 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Kilitch Drugs (India) Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Kilitch Drugs (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Kilitch Drugs (India) Ltd?

As of May 5, 2026, the Dr Reddys Laboratories Ltd stock price is INR ₹1270.95. On the other hand, Kilitch Drugs (India) Ltd stock price is INR ₹152.0.

How do dividend payouts of Dr Reddys Laboratories Ltd and Kilitch Drugs (India) Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Kilitch Drugs (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.